Text Size

Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae

This study has been completed.
Sponsor:
Collaborators:
London School of Hygiene and Tropical Medicine
Medical Research Council Unit, The Gambia
Department of State for Health and Social Welfare, The Gambia
Information provided by:
Gates Malaria Partnership
ClinicalTrials.gov Identifier:
NCT00120809
First received: July 12, 2005
Last updated: July 18, 2005
Last verified: July 2005
History of Changes
  Purpose

Malaria is particularly harmful during pregnancy causing anemia in the mother and low birth weight which, in turn, increases infant mortality. Thus, the World Health Organization (WHO) now recommends that all pregnant women who live in malaria endemic areas of Africa should receive sulfadoxine-pyrimethamine (SP) at monthly intervals during the second and third trimesters of pregnancy. Malaria is especially severe during first pregnancies and the value of intermittent preventative treatment with SP during first pregnancies has been clearly shown. However, it is less certain whether multigravidae, who are at less risk, also benefit from intermittent preventative treatment with SP. To investigate this, a trial has been conducted in Gambian multigravidae who were given intermittent preventative treatment with SP or placebo during the second and third trimesters. The prevalence of anemia six weeks after delivery, low birth weight and poor outcome of pregnancy in women in each group were studied.


Condition Intervention Phase
Malaria
 Drug: Sulfadoxine-pyrimethamine
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double-Blind
Primary Purpose: Prevention
Official Title: A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae.

Resource links provided by NLM:

MedlinePlus related topics: Malaria
U.S. FDA Resources

Further study details as provided by Gates Malaria Partnership:

Primary Outcome Measures:
  • Hemoglobin concentration at delivery.
  • Birthweight.

Secondary Outcome Measures:
  • Hemoglobin concentration six weeks after delivery.

Estimated Enrollment: 3000
Study Start Date: July 2002
Estimated Study Completion Date: September 2004
  Show Detailed Description

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Multigravid pregnancy.
  • Residence in study area.
  • Informed consent.

Exclusion Criteria:

  • Allergy to sulfonamides.
  • Chronic illness.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00120809

Locations
Gambia
Medical Research Council Laboratories
Banjul, Gambia, PO Box 273
Sponsors and Collaborators
Gates Malaria Partnership
London School of Hygiene and Tropical Medicine
Medical Research Council Unit, The Gambia
Department of State for Health and Social Welfare, The Gambia
Investigators
Study Chair: Brian Greenwood, MD London School of Hygiene and Tropical Medicine
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00120809     History of Changes
Other Study ID Numbers: ITCRVG27b
Study First Received: July 12, 2005
Last Updated: July 18, 2005
Health Authority: Gambia: Department of State for Health and Social Welfare

Keywords provided by Gates Malaria Partnership:
Malaria
Pregnancy
Multigravidae
Intermittent preventative treatment
Sulfadoxine-pyrimethamine

Additional relevant MeSH terms:
Malaria
Protozoan Infections
Parasitic Diseases
Pyrimethamine
Sulfadoxine
Sulfadoxine-pyrimethamine
Antimalarials
Antiprotozoal Agents
Antiparasitic Agents
 Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents, Urinary
Renal Agents

ClinicalTrials.gov processed this record on October 16, 2012